Key Drivers
- Margin Expansion
- Cash Flow
- Liquidity Strength
AIAI Summary
CLOV has shifted from a speculative turnaround to a real operating inflection, with Q1 2026 GAAP profitability, positive free cash flow, and a 4.5-star Medicare upgrade showing scale is finally converting into economics—but the stock is now a “prove-it” story because durable claims discipline, not growth alone, will determine whether these gains hold.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Cash Flow
- •Liquidity Strength
CLOV delivered a strong Q1 2026 turnaround with higher margins, positive operating income and free cash flow, and solid liquidity, though leverage and a large accumulated deficit still temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Overbought momentum
- •Resistance ceiling
CLOV remains technically constructive above $5.20, but the sharp 44% rally and $5.39-$5.41 resistance make a near-term consolidation or pullback likely.
Fast rally from $3.65 to $5.26 signals stretched short-term momentum risk
Sentiment & News
Key News Insights:
- •Star Rating Boost
- •Insider Selling
- •Mixed Signal
Clover Health shares jumped after a court-ordered CMS upgrade lifted its PPO Medicare Star Rating to 4.5 stars, but a later director stock sale added a mixed insider-sentiment signal.
The rating upgrade is a clear near-term positive for sentiment and valuation, though the insider sale may temper enthusiasm
Similar Companies in Healthcare
Other companies in the same sector with AI ratings